Enanta Pharmaceuticals, Inc.
ENTA
$13.02
$0.221.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.55% | 1.91% | -12.48% | -5.80% | -22.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.55% | 1.91% | -12.48% | -5.80% | -22.84% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3.55% | 1.91% | -12.48% | -5.80% | -22.84% |
| SG&A Expenses | -29.09% | -25.47% | -20.00% | -22.23% | -0.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.63% | -11.74% | -20.81% | -23.42% | -11.01% |
| Operating Income | 38.41% | 21.88% | 25.14% | 32.51% | 3.79% |
| Income Before Tax | 36.04% | 20.94% | 24.02% | 33.27% | 1.12% |
| Income Tax Expenses | 108.82% | 107.34% | -259.50% | 33.12% | 74.26% |
| Earnings from Continuing Operations | 35.12% | 19.43% | 27.32% | 33.28% | -2.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.12% | 19.43% | 27.32% | 33.28% | -2.55% |
| EBIT | 38.41% | 21.88% | 25.14% | 32.51% | 3.79% |
| EBITDA | 41.78% | 25.04% | 27.44% | 33.85% | 3.25% |
| EPS Basic | 35.70% | 20.17% | 27.96% | 33.75% | -1.90% |
| Normalized Basic EPS | 35.99% | 21.67% | 24.69% | 35.07% | 6.72% |
| EPS Diluted | 35.70% | 20.17% | 27.96% | 33.75% | -1.90% |
| Normalized Diluted EPS | 35.99% | 21.67% | 24.69% | 35.07% | 6.72% |
| Average Basic Shares Outstanding | 0.90% | 0.93% | 0.89% | 0.71% | 0.63% |
| Average Diluted Shares Outstanding | 0.90% | 0.93% | 0.89% | 0.71% | 0.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |